Value of Analysing Under-utilised Leftover Tissue (VauLT)

Recruiting now

Conditions studied: Oncology

In brief

Intratumour heterogeneity is well recognized in multiple cancer types and ultimately leads to therapeutic resistance. It also limits the ability of small samples to represent the whole tumour, having implications for diagnosis, molecular analysis and understanding of the tumour immune microenvironment. By blending- 'homogenizing'- leftover tumour tissue in excess of that required for diagnosistic purposes, one may create a more representative sample for analysis.

Key facts

Study ID

NCT03832062

Run by

Royal Marsden NHS Foundation Trust

People needed

800

Starts

2018-09-10

Expected to finish

2028-12-31

Last updated by the study team

2025-05-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Leftover formalin-fixed tissue (ie that would be otherwise discarded by histopathology) from cancer surgery.
• Tissues for Research consent has been provided.
• Patient age >18yo.
• Minimum of 1 gram of residual tumour remaining in leftover surgical tissue
• Minimum of 1 gram of normal tissue present.

You may not qualify if…

• Advanced Practitioner in histological dissection deems tumour sample to be inadequate.
• Leftover surgical tumour tissue greater than 20kg.

Where it is running

• Royal Marsden Hospital NHS Foundation Trust — London, United Kingdom (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.